LadaTech Patent Infringed by Illumina, Federal Jury Rules

LadaTech LLC, a biotech company partly owned by GlaxoSmithKline Plc (GSK), won a jury verdict that rival Illumina Inc. infringed a patent for gene-manipulation techniques used in diagnosing disease.

The jury in federal court in Wilmington, Delaware, also decided that the patent owned by LadaTech, of Larchmont, New York, is valid and enforceable, according to court papers.

LadaTech sued San Diego-based Illumina in 2009. The trial was supervised by U.S. District Judge Sue Robinson. The jury didn’t rule on damages. That phase of the case hasn’t been scheduled.

“This verdict is an important reaffirmation of the importance of the LadaTech patent” Chief Executive Officer Nicholas Didier said in a statement today.

Illumina intends to appeal the jury’s finding of infringement, the company said in a statement.

“We believe that we acted properly with respect to the LadaTech patent and that, ultimately, our position will be vindicated,” Jay Flatley, Illumina’s chief executive, said in a statement.

The case is LadaTech LLC v. Illumina Inc. (ILMN), 09CV627, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 6,107,023.

To contact the reporters on this story: Dawn McCarty in Wilmington at dmccarty@bloomberg.net; Phil Milford in Wilmington at pmilford@bloomberg.net.

To contact the editor responsible for this story: John Pickering at jpickering@bloomberg.net; Michael Hytha at mhytha@bloomberg.net.

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.